+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Gene Therapy Market

  • PDF Icon

    Report

  • 300 Pages
  • September 2022
  • Region: Global
  • Future Market Insights
  • ID: 5713590
A recent market study published by the publisher on Cancer Gene Therapy offers a global industry analysis for 2017-2021 and opportunity assessment for 2022-2032. The study offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical and current growth parameters, the growth prospects of the market are obtained with maximum precision.

Market Segmentation

The global Cancer Gene Therapy Market is segmented in detail to cover every aspect of the market and present complete market intelligence to readers

By Therapy

  • Gene Induced Immunotherapy
  • Oncolytic Virotherapy
  • Gene Transfer
  • Others

By Indication

  • Breast Cancer
  • Ovarian Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Lung Cancer
  • Prostate Cancer

By Service Provider

  • Hospitals
  • Clinical Research Laboratory
  • Oncology institutes

By Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa (MEA)

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations

2. Market Overview
2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation/Development Trends

4. Key Success Factors
4.1. Technology Assessment
4.2. Disease Epidemiology
4.3. Regulatory Landscape
4.4. Reimbursement Outlook
4.5. Key Marketing & Promotional Strategies Adopted By Companies
4.6. PESTLE Analysis
4.7. Porter’s Analysis

5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Rise in Healthcare Spending
5.1.3. Global Expenditure on Healthcare Infrastructure
5.2. Forecast Factors - Relevance & Impact
5.2.1. Mergers and Acquisitions
5.2.2. Disease Prevalence and Growth
5.2.3. R&D for Cancer Gene Therapy
5.2.4. Technological Advancements
5.2.5. Regulatory Framework
5.2.6. Reimbursement Policies
5.2.7. Prevalence of Geriatric Age Group
5.2.8. Global Burden of Cancer
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Therapy
6.1.2. Revenue By Indication
6.1.3. Revenue By Service Provider
6.1.4. Revenue By Country
6.2. 2021 Market Scenario

7. Global Market Demand (in Value or Size in US$ Bn) Analysis 2017-2021 and Forecast, 2022-2032
7.1. Historical Market Value (US$ Bn) Analysis, 2017-2021
7.2. Current and Future Market Value (US$ Bn) Projections, 2022-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Therapy
8.1. Introduction/Key Findings
8.2. Historical Market Size (US$ Bn) Trend Analysis, By Therapy, 2017-2021
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Therapy, 2022-2032
8.3.1. Gene Induced Immunotherapy
8.3.2. Oncolytic Virotherapy
8.3.3. Gene Transfer
8.3.4. Others
8.4. Market Attractiveness Analysis By Therapy

9. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Indication
9.1. Introduction/Key Findings
9.2. Historical Market Size (US$ Bn) Trend Analysis, By Indication, 2017-2021
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Indication, 2022-2032
9.3.1. Breast Cancer
9.3.2. Ovarian Cancer
9.3.3. Liver Cancer
9.3.4. Pancreatic Cancer
9.3.5. Lung Cancer
9.3.6. Prostate Cancer
9.4. Market Attractiveness Analysis By Indication

10. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Service Provider
10.1. Introduction/Key Findings
10.2. Historical Market Size (US$ Bn) Trend Analysis, By Service Provider, 2017-2021
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Service Provider, 2022-2032
10.3.1. Hospitals
10.3.2. Clinical Research Laboratory
10.3.3. Oncology institutes
10.4. Market Attractiveness Analysis By Service Provider

11. Global Market Analysis 2017-2021 and Forecast 2022-2032, by Region
11.1. Introduction
11.2. Historical Market Size (US$ Bn) Analysis, By Region, 2017-2021
11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2022-2032
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia
11.3.6. Oceania
11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region

12. North America Market Analysis 2017-2021 and Forecast 2022-2032
12.1. Introduction
12.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017-2021
12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022-2032
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Therapy
12.3.3. By Indication
12.3.4. By Service Provider
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Therapy
12.4.3. By Indication
12.4.4. By Service Provider
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. U.S. Market Analysis
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Therapy
12.8.1.2.2. By Indication
12.8.1.2.3. By Service Provider
12.8.2. Canada Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Therapy
12.8.2.2.2. By Indication
12.8.2.2.3. By Service Provider

13. Latin America Market Analysis 2017-2021 and Forecast 2022-2032
13.1. Introduction
13.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017-2021
13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022-2032
13.3.1. By Country
13.3.1.1. Mexico
13.3.1.2. Brazil
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Therapy
13.3.3. By Indication
13.3.4. By Service Provider
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Therapy
13.4.3. By Indication
13.4.4. By Service Provider
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Mexico Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Therapy
13.8.1.2.2. By Indication
13.8.1.2.3. By Service Provider
13.8.2. Brazil Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Therapy
13.8.2.2.2. By Indication
13.8.2.2.3. By Service Provider
13.8.3. Argentina Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Therapy
13.8.3.2.2. By Indication
13.8.3.2.3. By Service Provider

14. Europe Market Analysis 2017-2021 and Forecast 2022-2032
14.1. Introduction
14.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017-2021
14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022-2032
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. U.K.
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Nordic Countries
14.3.1.8. Russia
14.3.1.9. Rest of Europe
14.3.2. By Therapy
14.3.3. By Indication
14.3.4. By Service Provider
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Therapy
14.4.3. By Indication
14.4.4. By Service Provider
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Germany Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Therapy
14.8.1.2.2. By Indication
14.8.1.2.3. By Service Provider
14.8.2. Italy Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Therapy
14.8.2.2.2. By Indication
14.8.2.2.3. By Service Provider
14.8.3. France Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Therapy
14.8.3.2.2. By Indication
14.8.3.2.3. By Service Provider
14.8.4. U.K. Market Analysis
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Therapy
14.8.4.2.2. By Indication
14.8.4.2.3. By Service Provider
14.8.5. Spain Market Analysis
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Therapy
14.8.5.2.2. By Indication
14.8.5.2.3. By Service Provider
14.8.6. BENELUX Market Analysis
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Therapy
14.8.6.2.2. By Indication
14.8.6.2.3. By Service Provider
14.8.7. Nordic Countries Contact Lenses Market Analysis
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Therapy
14.8.7.2.2. By Indication
14.8.7.2.3. By Service Provider
14.8.8. Russia Market Analysis
14.8.8.1. Introduction
14.8.8.2. Market Analysis and Forecast by Market Taxonomy
14.8.8.2.1. By Therapy
14.8.8.2.2. By Indication
14.8.8.2.3. By Service Provider

15. East Asia Market Analysis 2017-2021 and Forecast 2022-2032
15.1. Introduction
15.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017-2021
15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022-2032
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Therapy
15.3.3. By Indication
15.3.4. By Service Provider
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Therapy
15.4.3. By Indication
15.4.4. By Service Provider
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. China Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Therapy
15.8.1.2.2. By Indication
15.8.1.2.3. By Service Provider
15.8.2. Japan Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Therapy
15.8.2.2.2. By Indication
15.8.2.2.3. By Service Provider
15.8.3. South Korea Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Therapy
15.8.3.2.2. By Indication
15.8.3.2.3. By Service Provider

16. South Asia Market Analysis 2017-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017-2021
16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022-2032
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Philippines
16.3.1.5. Thailand
16.3.1.6. Vietnam
16.3.1.7. Rest of South Asia
16.3.2. By Therapy
16.3.3. By Indication
16.3.4. By Service Provider
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Therapy
16.4.3. By Indication
16.4.4. By Service Provider
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Therapy
16.8.1.2.2. By Indication
16.8.1.2.3. By Service Provider
16.8.2. Indonesia Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Therapy
16.8.2.2.2. By Indication
16.8.2.2.3. By Service Provider
16.8.3. Malaysia Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Therapy
16.8.3.2.2. By Indication
16.8.3.2.3. By Service Provider
16.8.4. Philippines Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Therapy
16.8.4.2.2. By Indication
16.8.4.2.3. By Service Provider
16.8.5. Thailand Market Analysis
16.8.5.1. Introduction
16.8.5.2. Market Analysis and Forecast by Market Taxonomy
16.8.5.2.1. By Therapy
16.8.5.2.2. By Indication
16.8.5.2.3. By Service Provider
16.8.6. Vietnam Market Analysis
16.8.6.1. Introduction
16.8.6.2. Market Analysis and Forecast by Market Taxonomy
16.8.6.2.1. By Therapy
16.8.6.2.2. By Indication
16.8.6.2.3. By Service Provider

17. Oceania Market 2012-2021 and Forecast 2022-2032
17.1. Introduction
17.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017-2021
17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022-2032
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Therapy
17.3.3. By Indication
17.3.4. By Service Provider
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Therapy
17.4.3. By Indication
17.4.4. By Service Provider
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Australia Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Therapy
17.8.1.2.2. By Indication
17.8.1.2.3. By Service Provider
17.8.2. New Zealand Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Therapy
17.8.2.2.2. By Indication
17.8.2.2.3. By Service Provider

18. Middle East and Africa (MEA) Market Analysis 2017-2021 and Forecast 2022-2032
18.1. Introduction
18.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017-2021
18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022-2032
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Israel
18.3.1.3. Turkey
18.3.1.4. South Africa
18.3.1.5. North Africa
18.3.1.6. Rest of Middle East and Africa
18.3.2. By Therapy
18.3.3. By Indication
18.3.4. By Service Provider
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Therapy
18.4.3. By Indication
18.4.4. By Service Provider
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. GCC Countries Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Therapy
18.8.1.2.2. By Indication
18.8.1.2.3. By Service Provider
18.8.2. Israel Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Therapy
18.8.2.2.2. By Indication
18.8.2.2.3. By Service Provider
18.8.3. Turkey Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Therapy
18.8.3.2.2. By Indication
18.8.3.2.3. By Service Provider
18.8.4. South Africa Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Therapy
18.8.4.2.2. By Indication
18.8.4.2.3. By Service Provider
18.8.5. North Africa Market Analysis
18.8.5.1. Introduction
18.8.5.2. Market Analysis and Forecast by Market Taxonomy
18.8.5.2.1. By Therapy
18.8.5.2.2. By Indication
18.8.5.2.3. By Service Provider

19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Presence Analysis

20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive
20.3.1. Merck KGaA
20.3.1.1. Overview
20.3.1.2. Product Portfolio
20.3.1.3. Profitability by Market Segments (Product/Channel/Region)
20.3.1.4. Sales Footprint
20.3.1.5. Key Financials
20.3.1.6. SWOT Analysis
20.3.1.7. Strategy Overview
20.3.2. Novartis AG
20.3.2.1. Overview
20.3.2.2. Product Portfolio
20.3.2.3. Profitability by Market Segments (Product/Channel/Region)
20.3.2.4. Sales Footprint
20.3.2.5. Key Financials
20.3.2.6. SWOT Analysis
20.3.2.7. Strategy Overview
20.3.3. AstraZeneca Plc
20.3.3.1. Overview
20.3.3.2. Product Portfolio
20.3.3.3. Profitability by Market Segments (Product/Channel/Region)
20.3.3.4. Sales Footprint
20.3.3.5. Key Financials
20.3.3.6. SWOT Analysis
20.3.3.7. Strategy Overview
20.3.4. BIOCAD
20.3.4.1. Overview
20.3.4.2. Product Portfolio
20.3.4.3. Profitability by Market Segments (Product/Channel/Region)
20.3.4.4. Sales Footprint
20.3.4.5. Key Financials
20.3.4.6. SWOT Analysis
20.3.4.7. Strategy Overview
20.3.5. Crinetics Pharmaceuticals, Inc.
20.3.5.1. Overview
20.3.5.2. Product Portfolio
20.3.5.3. Profitability by Market Segments (Product/Channel/Region)
20.3.5.4. Sales Footprint
20.3.5.5. Key Financials
20.3.5.6. SWOT Analysis
20.3.5.7. Strategy Overview
20.3.6. EffRx Pharmaceuticals S.A.
20.3.6.1. Overview
20.3.6.2. Product Portfolio
20.3.6.3. Profitability by Market Segments (Product/Channel/Region)
20.3.6.4. Sales Footprint
20.3.6.5. Key Financials
20.3.6.6. SWOT Analysis
20.3.6.7. Strategy Overview
20.3.7. Euroscreen S.A.
20.3.7.1. Overview
20.3.7.2. Product Portfolio
20.3.7.3. Profitability by Market Segments (Product/Channel/Region)
20.3.7.4. Sales Footprint
20.3.7.5. Key Financials
20.3.7.6. SWOT Analysis
20.3.7.7. Strategy Overview
20.3.8. Vicore Pharma AB
20.3.8.1. Overview
20.3.8.2. Product Portfolio
20.3.8.3. Profitability by Market Segments (Product/Channel/Region)
20.3.8.4. Sales Footprint
20.3.8.5. Key Financials
20.3.8.6. SWOT Analysis
20.3.8.7. Strategy Overview
20.3.9. Amgen
20.3.9.1. Overview
20.3.9.2. Product Portfolio
20.3.9.3. Profitability by Market Segments (Product/Channel/Region)
20.3.9.4. Sales Footprint
20.3.9.5. Key Financials
20.3.9.6. SWOT Analysis
20.3.9.7. Strategy Overview
20.3.10. Bristol-Myers Squibb
20.3.10.1. Overview
20.3.10.2. Product Portfolio
20.3.10.3. Profitability by Market Segments (Product/Channel/Region)
20.3.10.4. Sales Footprint
20.3.10.5. Key Financials
20.3.10.6. SWOT Analysis
20.3.10.7. Strategy Overview
20.3.11. Cell Genesys Inc.
20.3.11.1. Overview
20.3.11.2. Product Portfolio
20.3.11.3. Profitability by Market Segments (Product/Channel/Region)
20.3.11.4. Sales Footprint
20.3.11.5. Key Financials
20.3.11.6. SWOT Analysis
20.3.11.7. Strategy Overview
20.3.12. Adaptimmune Therapeutics plc
20.3.12.1. Overview
20.3.12.2. Product Portfolio
20.3.12.3. Profitability by Market Segments (Product/Channel/Region)
20.3.12.4. Sales Footprint
20.3.12.5. Key Financials
20.3.12.6. SWOT Analysis
20.3.12.7. Strategy Overview
20.3.13. Achieve Life Science Inc.
20.3.13.1. Overview
20.3.13.2. Product Portfolio
20.3.13.3. Profitability by Market Segments (Product/Channel/Region)
20.3.13.4. Sales Footprint
20.3.13.5. Key Financials
20.3.13.6. SWOT Analysis
20.3.13.7. Strategy Overview
20.3.14. BioCanCell Ltd.
20.3.14.1. Overview
20.3.14.2. Product Portfolio
20.3.14.3. Profitability by Market Segments (Product/Channel/Region)
20.3.14.4. Sales Footprint
20.3.14.5. Key Financials
20.3.14.6. SWOT Analysis
20.3.14.7. Strategy Overview
20.3.15. Genelux Corporation
20.3.15.1. Overview
20.3.15.2. Product Portfolio
20.3.15.3. Profitability by Market Segments (Product/Channel/Region)
20.3.15.4. Sales Footprint
20.3.15.5. Key Financials
20.3.15.6. SWOT Analysis
20.3.15.7. Strategy Overview
20.3.16. Advantagene Inc.,
20.3.16.1. Overview
20.3.16.2. Product Portfolio
20.3.16.3. Profitability by Market Segments (Product/Channel/Region)
20.3.16.4. Sales Footprint
20.3.16.5. Key Financials
20.3.16.6. SWOT Analysis
20.3.16.7. Strategy Overview
20.3.17. GenVec Inc.
20.3.17.1. Overview
20.3.17.2. Product Portfolio
20.3.17.3. Profitability by Market Segments (Product/Channel/Region)
20.3.17.4. Sales Footprint
20.3.17.5. Key Financials
20.3.17.6. SWOT Analysis
20.3.17.7. Strategy Overview
20.3.18. Glaxosmithkline PLC
20.3.18.1. Overview
20.3.18.2. Product Portfolio
20.3.18.3. Profitability by Market Segments (Product/Channel/Region)
20.3.18.4. Sales Footprint
20.3.18.5. Key Financials
20.3.18.6. SWOT Analysis
20.3.18.7. Strategy Overview
20.3.19. Amgen Inc.
20.3.19.1. Overview
20.3.19.2. Product Portfolio
20.3.19.3. Profitability by Market Segments (Product/Channel/Region)
20.3.19.4. Sales Footprint
20.3.19.5. Key Financials
20.3.19.6. SWOT Analysis
20.3.19.7. Strategy Overview

21. Assumptions and Acronyms Used

22. Research Methodology

Companies Mentioned

  • Merck KGaA
  • Novartis AG
  • AstraZeneca Plc.
  • BIOCAD
  • Crinetics Pharmaceuticals, Inc.
  • EffRx Pharmaceuticals S.A.
  • Euroscreen S.A.
  • Vicore Pharma AB
  • Amgen
  • Bristol-Myers Squibb
  • Cell Genesys Inc.
  • Adaptimmune Therapeutics plc.
  • Achieve Life Science Inc.
  • BioCanCell Ltd.
  • Genelux Corporation
  • Advantagene Inc.,
  • GenVec Inc.
  • GlaxoSmithKline PLC
  • Amgen Inc.